Table 2: Responses to neoadjuvant chemotherapy in differentiated thyroid cancer.

Author and yearSample size InterventionResponse

Besic et al., 2012 [11]29 with T3 or T4 follicular or Hurthle cell thyroid cancer.Vinblastine, vinblastine with doxorubicin, or other regimens.RR 44.8%.
Besic et al., 2013 [12]16 with T3 or T4 papillary thyroid cancer.Vinblastine, vinblastine with doxorubicin, or other regimens. RR 40%.
Ito  et al., 2012 [13]2 with papillary thyroid cancer with a squamous cell carcinoma component.Paclitaxel 80 mg/m2.50% PR, 50% SD.

Definitions: PR: partial response, RR: response rate, defined as decrease in tumor size by >50%, and SD: stable disease.